ARCT Arcturus Therapeutics Holdings Inc

Price (delayed)

$35.09

Market cap

$923.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.98

Enterprise value

$520.6M

Highlights
The company's EPS has shrunk by 135% YoY and by 40% QoQ
The net income has dropped by 65% since the previous quarter

Key stats

What are the main financial stats of ARCT
Market
Shares outstanding
26.32M
Market cap
$923.58M
Enterprise value
$520.6M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.62
Price to sales (P/S)
102.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
57.72
Earnings
Revenue
$9.02M
EBIT
-$118.15M
EBITDA
-$117.14M
Free cash flow
-$75.67M
Per share
EPS
-$4.98
Free cash flow per share
-$2.88
Book value per share
$13.42
Revenue per share
$0.34
TBVPS
$18.35
Balance sheet
Total assets
$481.47M
Total liabilities
$128.86M
Debt
$63.86M
Equity
$352.61M
Working capital
$416.66M
Liquidity
Debt to equity
0.18
Current ratio
8.81
Quick ratio
8.79
Net debt/EBITDA
3.44
Margins
EBITDA margin
-1,298.7%
Gross margin
100%
Net margin
-1,316.2%
Operating margin
-1,327.4%
Efficiency
Return on assets
-33.2%
Return on equity
-43%
Return on invested capital
-1,968.5%
Return on capital employed
-27.6%
Return on sales
-1,309.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
3.54%
1 week
2.04%
1 month
13.85%
1 year
-12.41%
YTD
-19.11%
QTD
-15.04%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$9.02M
Gross profit
$9.02M
Operating income
-$119.73M
Net income
-$118.72M
Gross margin
100%
Net margin
-1,316.2%
Arcturus Therapeutics Holdings's operating margin has shrunk by 77% QoQ
Arcturus Therapeutics Holdings's net margin has shrunk by 74% QoQ
Arcturus Therapeutics Holdings's operating income has shrunk by 67% QoQ
The net income has dropped by 65% since the previous quarter

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
2.62
P/S
102.09
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
57.72
The company's EPS has shrunk by 135% YoY and by 40% QoQ
ARCT's P/B is 47% lower than its last 4 quarters average of 4.9
ARCT's equity is down by 11% since the previous quarter
The revenue has dropped by 53% year-on-year and by 5% since the previous quarter
ARCT's price to sales (P/S) is 6% higher than its last 4 quarters average of 96.6

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
The company's return on sales has shrunk by 74% QoQ
The company's return on equity has surged by 63% YoY but it fell by 15% QoQ
Arcturus Therapeutics Holdings's ROIC has increased by 35% from the previous quarter
The ROA has decreased by 17% QoQ but it has increased by 10% YoY

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
ARCT's current ratio has soared by 200% YoY but it is down by 7% QoQ
Arcturus Therapeutics Holdings's total liabilities has surged by 134% YoY and by 61% QoQ
Arcturus Therapeutics Holdings's debt is 82% lower than its equity
The debt to equity has plunged by 84% YoY
ARCT's equity is down by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.